Interestingly, this mutation can be successfully targeted by 3rd generation EGFR TKIs, such as osimertinib (Astra-Zeneca, United Kingdom), the administration of which is currently approved in the context of advanced NSCLC [4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.